#United States #San Francisco #biotechnology #Divamics #DVI-001

Divamics Unveils DVI-001 and DVI-004 at JPM Week 2026

In an extraordinary presentation during the Biotech Showcase™ at JPM Week 2026, Divamics, an innovative biotech firm harnessing artificial intelligence for molecular discovery, pushed the boundaries of therapeutic development by spotlighting its lead autoimmune candidate, DVI-001, along with its newly introduced metabolic program, DVI-004. The dual focus on advancing their research pipeline illustrates the company's commitment to addressing complex health challenges.

The Journey to DVI-001

Divamics has emerged as a key player in biotechnology since its inception in 2021. The company's leadership, particularly CEO Dr. John Zheng, has a storied history in computational chemistry, having contributed significantly during his tenure in the United States, including the creation of the MovableType free energy algorithm, which garnered accolades in the international SAMPL6 drug design challenge.

DVI-001 signifies not only the culmination of scientific expertise but also serves as the cornerstone of Divamics' strategy to leverage AI in drug development. This novel treatment has shown promising results in preliminary trials, demonstrating efficacy in targeting autoimmune disorders. The integration of AI enables Divamics to streamline the research process, making predictions with high accuracy and ultimately leading to clinical-ready assets.

The Launch of DVI-004

During the showcase, Divamics also revealed DVI-004, a program aimed at metabolic diseases generated through their proprietary AI platform. This new offering highlights the versatility of Divamics' technology in addressing various health issues beyond autoimmune conditions. By harnessing machine learning alongside molecular dynamics, the company has positioned itself to facilitate a rapid transition from the identification of hits to the selection of preclinical candidates.

Collaboration and Market Position

The showcase was not merely a platform for Divamics to present its innovations but also an opportunity to highlight its collaborative efforts and market validation. The company shared insights on its fruitful partnership with BrightGene, culminating in peer-reviewed research published in the Journal of Medicinal Chemistry in 2025. Throughout JPM Week, Divamics conducted over 50 high-level meetings with influential stakeholders, reinforcing its position in the competitive biotech landscape.

Dr. Zheng emphasized, "JPM Week is the perfect venue for us to display our advancements to the global life sciences community. Our combined U.S. scientific expertise and China’s agile biotech infrastructure offer a unique value proposition for high-precision molecular discovery, ensuring capital efficiency and quick execution."

Divamics operates with a strategically global footprint, housing its headquarters in Suzhou, with operational teams spread across Shanghai, Beijing, and a hub in Singapore dedicated to fostering international research and development collaborations.

Conclusion

Divamics exemplifies the future of biotechnology, where AI-driven methodologies not only streamline processes but also enhance therapeutic innovation. With its dual program highlights of DVI-001 and DVI-004, the firm is set to make waves in the biotech industry, driving forward the important work needed in autoimmune and metabolic disease solutions. As they continue to break new ground, both industry partners and patients can look forward to a promising future of precision medicine.